Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Lawson

Showing results (101-110 of 128) with videos related to

Pageof 13
Sort By:
Bioinformatics (Oxford, England)|August 18, 2004
DisProt: a database of protein disorderSlobodan Vucetic, Zoran Obradovic, Vladimir Vacic, et al.
Journal of Medicinal Chemistry|August 27, 2021
Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (<i>S</i>)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3<i>H</i>-1,2,4-triazol-3-one, by Fragment-Based Drug DesignMark Sabat, Douglas R Dougan, Beverly Knight, et al.
Journal of Chemical Information and Modeling|October 17, 2024
Exploration of Cryptic Pockets Using Enhanced Sampling Along Normal Modes: A Case Study of KRAS <sup>G12D</sup>Neha Vithani, She Zhang, Jeffrey P Thompson, et al.
Frontiers in Public Health|July 3, 2025
Monitoring and enforcement of Code-based legal measures to protect breastfeeding in South Asia: opportunities and bottlenecksConstance Ching, Vani Sethi, David Lawson Clark, et al.
Molecular Cancer Therapeutics|March 26, 2017
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF AntibodyPamela J Farrell, Jennifer Matuszkiewicz, Deepika Balakrishna, et al.
RSC Medicinal Chemistry|December 22, 2022
Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hitsChristopher R Smith, Svitlana Kulyk, Misbha Ud Din Ahmad, et al.
Bioorganic & Medicinal Chemistry Letters|May 9, 2016
Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1Zacharia Cheruvallath, Mingnam Tang, Christopher McBride, et al.
Brain Stimulation|April 22, 2026
Circuit-Informed Targeting for Psychiatric Comorbidity in Depression: An Accelerated TMS Pilot StudyLauren Sanderson, Anjali Chandra, Emma Jones, et al.
Journal of Medicinal Chemistry|October 28, 2021
Correction to "Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (<i>S</i>)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3<i>H</i>-1,2,4-triazol-3-one, by Fragment-Based Drug Design"Mark Sabat, Douglas R Dougan, Jacques Ermolieff, et al.
Bioorganic & Medicinal Chemistry|August 4, 2022
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitorsChristopher R Smith, Ruth Aranda, James G Christensen, et al.
Pageof 13

Showing results (101-110 of 128) with videos related to

Sort By:
Pageof 13
Bioinformatics (Oxford, England)|August 18, 2004
DisProt: a database of protein disorderSlobodan Vucetic, Zoran Obradovic, Vladimir Vacic, et al.
Journal of Medicinal Chemistry|August 27, 2021
Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (<i>S</i>)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3<i>H</i>-1,2,4-triazol-3-one, by Fragment-Based Drug DesignMark Sabat, Douglas R Dougan, Beverly Knight, et al.
Journal of Chemical Information and Modeling|October 17, 2024
Exploration of Cryptic Pockets Using Enhanced Sampling Along Normal Modes: A Case Study of KRAS <sup>G12D</sup>Neha Vithani, She Zhang, Jeffrey P Thompson, et al.
Frontiers in Public Health|July 3, 2025
Monitoring and enforcement of Code-based legal measures to protect breastfeeding in South Asia: opportunities and bottlenecksConstance Ching, Vani Sethi, David Lawson Clark, et al.
Molecular Cancer Therapeutics|March 26, 2017
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF AntibodyPamela J Farrell, Jennifer Matuszkiewicz, Deepika Balakrishna, et al.
RSC Medicinal Chemistry|December 22, 2022
Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hitsChristopher R Smith, Svitlana Kulyk, Misbha Ud Din Ahmad, et al.
Bioorganic & Medicinal Chemistry Letters|May 9, 2016
Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1Zacharia Cheruvallath, Mingnam Tang, Christopher McBride, et al.
Brain Stimulation|April 22, 2026
Circuit-Informed Targeting for Psychiatric Comorbidity in Depression: An Accelerated TMS Pilot StudyLauren Sanderson, Anjali Chandra, Emma Jones, et al.
Journal of Medicinal Chemistry|October 28, 2021
Correction to "Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (<i>S</i>)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3<i>H</i>-1,2,4-triazol-3-one, by Fragment-Based Drug Design"Mark Sabat, Douglas R Dougan, Jacques Ermolieff, et al.
Bioorganic & Medicinal Chemistry|August 4, 2022
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitorsChristopher R Smith, Ruth Aranda, James G Christensen, et al.
Pageof 13